Dissecting enzyme function at scale using synergistic advances in microfluidics and genetic code expansion
- Institution
- Stanford University, CA
- Principal investigator
- Patrick James Almhjell
- Funding
- $76K
- Duration
- 2024–2026
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY. Noncanonical amino acids (ncAAs) have myriad valuable applications in the biochemical and biophysical sciences. Their site-specific incorporation into proteins of interest can directly install systematically perturbed residues, sensitive biophysical probes, bio-orthogonal handles, and post-translational modifications (PTMs) at positions of interest. While promising, these applications have been greatly limited by costly materials and labor- intensive, low-yielding preparations. To realize the full potential of ncAAs, I will leverage the recently developed high-throughput microfluidic enzyme kinetics (HT-MEK) platform from the Fordyce and Herschlag laboratories at Stanford University to enable the parallel expression, purification, and quantitative assay of >1,000 ncAA- harboring protein variants on a single microfluidic device. With this approach, it will become feasible and routine to collect >10,000 gold-standard biochemical measurements of ncAA-containing proteins while using less material and effort than is typically required to collect a single such measurement. To illustrate the power and utility of this technique, I will first apply it towards understanding the catalytic mechanisms governing proton transfer at carbon in the model system alanine racemase (AlaR), an important pyridoxal 5’-phosphate (PLP)-dependent enzyme involved in cell-wall biosynthesis. PLP-dependent enzymes account for 4% of all classified enzymatic activities and ~1.5% of prokaryotic reading frames, and they are increasingly important in biotechnology. Although we have a reasonable understanding of how the small- molecule cofactor itself can influence catalysis, the specific contributions of the protein scaffold remain speculative, qualitative, or both. Previous studies that have used traditional site-directed mutagenesis—altering many properties simultaneously—and only examined a handful of variants have failed to deliver a unified view of how this enzyme achieves its catalytic proficiency. Here, I will use ncAAs on the HT-MEK device to systematically and precisely perturb the electrostatic properties of critical catalytic residues in the active site of AlaR—leaving other steric properties largely unaltered—across 96 different enzyme variants. Specifically, I will investigate how interactions in the active site act together to optimize this difficult proton transfer to: (1) be highly efficient at neutral pH; and (2) achieve an exquisite 106:1 regioselectivity among competing pathways for reprotonation of the reactive intermediate. The new training that I obtain from this project will greatly and uniquely expand my skillset at the interface of biocatalysis and mechanistic enzymology, leaving me poised to achieve my long-term goal of creating new enzymes to address enduring and emergent challenges in the biological and chemical sciences. More broadly, the development of reliable methods for the quantitative, high-throughput assay of hundreds of ncAA-harboring proteins is expected to have far-reaching impacts in all areas of biochemical and biophysical research with significant applied and therapeutic relevance.
LOADING MOONBASE SCORE
Questions for Stanford University
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · Stanford University60
Dissecting neocortical field potential dynamics using optical voltage imaging in genetically targeted cell-types
Mark J Schnitzer · $604K · 2021–2027
- NIH · Stanford University48
Clinical Translation of Ultrasonic Ketamine Uncaging for Non-Opioid Therapy of Chronic Pain
Raag D Airan · $1.3M · 2019–2026
- NIH · Stanford University46
Innovating next generation technologies to define mechanisms of neurodegenerative disease and devise therapeutic strategies
Aaron D. Gitler · $1.1M · 2024–2032